No Data
No Data
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention.Investors are constantly o
Barclays Maintains Danaher(DHR.US) With Hold Rating, Maintains Target Price $270
Barclays analyst Luke Sergott maintains $Danaher(DHR.US)$ with a hold rating, and maintains the target price at $270.According to TipRanks data, the analyst has a success rate of 39.9% and a total ave
FDA Approves Danaher Unit's Rapid Test for Hepatitis C
By Paul Ziobro The Food and Drug Administration on Thursday granted marketing approval to Danaher's Cepheid unit for a rapid test for hepatitis C. The approval is for Cepheid's Xpert HCV test and Ge
FDA Grants Marketing Authorization To Cepheid For Xpert HCV Test And GeneXpert Xpress System, First Point-Of-Care Hepatitis C Test
FDA Grants Marketing Authorization To Cepheid For Xpert HCV Test And GeneXpert Xpress System, First Point-Of-Care Hepatitis C Test
Danaher To Go Ex-Dividend On June 28th, 2024 With 0.27 USD Dividend Per Share
June 26th (Eastern Time) - $Danaher(DHR.US)$ is trading ex-dividend on June 28th, 2024.Shareholders of record on June 28th, 2024 will receive 0.27 USD dividend per share on July 26th, 2024. The ex-div
Did Danaher Corporation (DHR) Get a Good Analyst Rating for Its Q1 Performance?
No Data